Kamei M, Matsuo K, Yoshida Y, Shimada K, et al. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells. Int J Cancer 2024;154:2176-2188.
PMID: 38346928